Senseonics Holdings, Inc. (SENS)
NYSEAMERICAN: SENS · Real-Time Price · USD
0.7371
+0.0441 (6.36%)
At close: Apr 23, 2025, 4:00 PM
0.7290
-0.0081 (-1.10%)
Pre-market: Apr 24, 2025, 8:12 AM EDT
Company Description
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
The company’s products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
The company was founded in 1996 and is headquartered in Germantown, Maryland.
Senseonics Holdings, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 117 |
| CEO | Timothy Goodnow |
Contact Details
Address: 20451 Seneca Meadows Parkway Germantown, Maryland 20876-7005 United States | |
| Phone | 301 515 7260 |
| Website | senseonics.com |
Stock Details
| Ticker Symbol | SENS |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001616543 |
| CUSIP Number | 81727U105 |
| ISIN Number | US81727U1051 |
| Employer ID | 47-1210911 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy T. Goodnow Ph.D. | President, Chief Executive Officer and Director |
| Dr. Mukul Jain Ph.D. | Chief Operating Officer |
| Kenneth L. Horton J.D. | General Counsel and Corporate Development Advisor |
| Dr. Francine Ratner Kaufman M.D. | Chief Medical Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | ARS | Filing |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Jan 17, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 6, 2024 | EFFECT | Notice of Effectiveness |
| Dec 3, 2024 | UPLOAD | Filing |